Limits...
Multicenter study for efficacy and safety evaluation of a fixeddose combination gel with adapalen 0.1% and benzoyl peroxide 2.5% (Epiduo® for the treatment of acne vulgaris in Brazilian population.

Sittart JA, Costa Ad, Mulinari-Brenner F, Follador I, Azulay-Abulafia L, Castro LC - An Bras Dermatol (2015)

Bottom Line: From 79 recruited patients, 73 concluded the study.There was significant, fast and progressive reduction of non-inflammatory, inflammatory and total number of lesions.The fixed-dose combination of adapalene 0.1% and benzoyl peroxide 2.5% gel is effective, safe, well tolerated and apparently improves patient compliance with the treatment.

View Article: PubMed Central - PubMed

Affiliation: Hospital do Servidor Público Estadual de São Paulo, São Paulo, SP, Brazil.

ABSTRACT

Background: The current options for the treatment of acne vulgaris present many mechanisms of action. For several times, dermatologists try topical agents combinations, looking for better results.

Objectives: To evaluate the efficacy, tolerability and safety of a topical, fixed-dose combination of adapalene 0.1% and benzoyl peroxide 2.5% gel for the treatment of acne vulgaris in the Brazilian population.

Methods: This is a multicenter, open-label and interventionist study. Patients applied 1.0 g of the fixed-dose combination of adapalene 0.1% and benzoyl peroxide 2.5% gel on the face, once daily at bedtime, during 12 weeks. Lesions were counted in all of the appointments, and the degree of acne severity, overall improvement, tolerability and safety were evaluated in each visit.

Results: From 79 recruited patients, 73 concluded the study. There was significant, fast and progressive reduction of non-inflammatory, inflammatory and total number of lesions. At the end of the study, 75.3% of patients had a reduction of >50% in non-inflammatory lesions, 69.9% in inflammatory lesions and 78.1% in total number of lesions. Of the 73 patients, 71.2% had good to excellent response and 87.6% had satisfactory to good response. In the first week of treatment, erythema, burning, scaling and dryness of the skin were frequent complaints, but, from second week on, these signals and symptoms have reduced.

Conclusion: The fixed-dose combination of adapalene 0.1% and benzoyl peroxide 2.5% gel is effective, safe, well tolerated and apparently improves patient compliance with the treatment.

No MeSH data available.


Related in: MedlinePlus

Patient photographed at baseline and at week 12 after initiation oftreatment
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4840853&req=5

f9: Patient photographed at baseline and at week 12 after initiation oftreatment

Mentions: As described in the literature, we found that the percentage of reduction in thenumber of lesions (noninflammatory, inflammatory and total) is maintained andprogressive over the 12 weeks, reaching 73.9% for inflammatory, 73% fornoninflammatory and 68.9% for total lesions in the last visit (Figures 4, 5 and 6). Thus, at week 12 the number of lesions wasstill decreasing. To obtain the proportion of patients who would have a goodresponse to treatment in terms of efficacy, we calculated the percentage of patientswith a reduction ≥50% in the number of noninflammatory, inflammatory andtotal lesions in week 12. We observed that 75.3% of patients had a reduction≥50% in noninflammatory lesions, 69.9% patients had a reduction ininflammatory lesions and 78% had a reduction in total lesions, which confirms theresults obtained from the percentage of patients who had an overall improvement fromgood to excellent (71.2%).


Multicenter study for efficacy and safety evaluation of a fixeddose combination gel with adapalen 0.1% and benzoyl peroxide 2.5% (Epiduo® for the treatment of acne vulgaris in Brazilian population.

Sittart JA, Costa Ad, Mulinari-Brenner F, Follador I, Azulay-Abulafia L, Castro LC - An Bras Dermatol (2015)

Patient photographed at baseline and at week 12 after initiation oftreatment
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4840853&req=5

f9: Patient photographed at baseline and at week 12 after initiation oftreatment
Mentions: As described in the literature, we found that the percentage of reduction in thenumber of lesions (noninflammatory, inflammatory and total) is maintained andprogressive over the 12 weeks, reaching 73.9% for inflammatory, 73% fornoninflammatory and 68.9% for total lesions in the last visit (Figures 4, 5 and 6). Thus, at week 12 the number of lesions wasstill decreasing. To obtain the proportion of patients who would have a goodresponse to treatment in terms of efficacy, we calculated the percentage of patientswith a reduction ≥50% in the number of noninflammatory, inflammatory andtotal lesions in week 12. We observed that 75.3% of patients had a reduction≥50% in noninflammatory lesions, 69.9% patients had a reduction ininflammatory lesions and 78% had a reduction in total lesions, which confirms theresults obtained from the percentage of patients who had an overall improvement fromgood to excellent (71.2%).

Bottom Line: From 79 recruited patients, 73 concluded the study.There was significant, fast and progressive reduction of non-inflammatory, inflammatory and total number of lesions.The fixed-dose combination of adapalene 0.1% and benzoyl peroxide 2.5% gel is effective, safe, well tolerated and apparently improves patient compliance with the treatment.

View Article: PubMed Central - PubMed

Affiliation: Hospital do Servidor Público Estadual de São Paulo, São Paulo, SP, Brazil.

ABSTRACT

Background: The current options for the treatment of acne vulgaris present many mechanisms of action. For several times, dermatologists try topical agents combinations, looking for better results.

Objectives: To evaluate the efficacy, tolerability and safety of a topical, fixed-dose combination of adapalene 0.1% and benzoyl peroxide 2.5% gel for the treatment of acne vulgaris in the Brazilian population.

Methods: This is a multicenter, open-label and interventionist study. Patients applied 1.0 g of the fixed-dose combination of adapalene 0.1% and benzoyl peroxide 2.5% gel on the face, once daily at bedtime, during 12 weeks. Lesions were counted in all of the appointments, and the degree of acne severity, overall improvement, tolerability and safety were evaluated in each visit.

Results: From 79 recruited patients, 73 concluded the study. There was significant, fast and progressive reduction of non-inflammatory, inflammatory and total number of lesions. At the end of the study, 75.3% of patients had a reduction of >50% in non-inflammatory lesions, 69.9% in inflammatory lesions and 78.1% in total number of lesions. Of the 73 patients, 71.2% had good to excellent response and 87.6% had satisfactory to good response. In the first week of treatment, erythema, burning, scaling and dryness of the skin were frequent complaints, but, from second week on, these signals and symptoms have reduced.

Conclusion: The fixed-dose combination of adapalene 0.1% and benzoyl peroxide 2.5% gel is effective, safe, well tolerated and apparently improves patient compliance with the treatment.

No MeSH data available.


Related in: MedlinePlus